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Abstract
In the last three decades, Clostridium difficile infection (CDI) has increased in incidence and severity in many countries
worldwide. The increase in CDI incidence has been particularly apparent among surgical patients. Therefore, prevention
of CDI and optimization of management in the surgical patient are paramount. An international multidisciplinary panel
of experts from the World Society of Emergency Surgery (WSES) updated its guidelines for management of CDI in
surgical patients according to the most recent available literature. The update includes recent changes introduced in
the management of this infection.
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Introduction
In the last three decades, the dramatic worldwide
increase in incidence and severity of Clostridium difficile
infection (CDI) [1] has made CDI a global public health
challenge [2–14]. Surgery is a known risk factor for
development of CDI yet surgery is also a treatment
option in severe cases of CDI [15–18]. The World Society
of Emergency Surgery (WSES) guidelines for management
of CDI in surgical patients were published in 2015 [19]. In
2019, the guidelines have been revised and updated. A
multidisciplinary expert panel worldwide prepared the
manuscript following an in-depth review of the most
recent current literature using MEDLINE, EMBASE, and
Cochrane Database and aimed to provide an insight into
these complex issues. The expert panel met via email to
prepare, discuss, and revise the paper. The manuscript
was successively reviewed by all members and ultimately
re-formulated as the present manuscript.
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These guidelines outline clinical recommendations
based on the Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) hierarchy cri-
teria from Guyatt et al. [20, 21] (Table 1).
Clostridioides difficile (formerly Clostridium difficile) is
an anaerobic, spore-forming, Gram-positive bacillus,
which may be part of the normal intestinal microbiota in
healthy babies [22–25]. The organism is spread via the
oral-fecal route and in hospitalized patients may be
acquired through the ingestion of spores from other
patients, healthcare personnel’s hands, or from environ-
mental surfaces [26, 27]. C. difficile is the main pathogen
associated with nosocomial infections and is the most
common cause of diarrhea in hospitalized patients [28].
CDI can present as a spectrum of symptoms ranging
from an asymptomatic carriage to fulminant disease with
toxic megacolon. The basis for this range of clinical
manifestations is not fully understood but is likely
related to host and pathogen interactions.
The rapid evolution of antibiotic resistance in C. difficile
and the consequent effects on prevention and treat-
ment of CDIs are a matter of concern for public
health. Multi-drug resistant (MDR) C. difficile strains
are increasing (about 60% of the epidemic strains
circulating in hospital settings show resistance to
three or more antibiotics) [29].
Pathogenesis
C. difficile spores survive the acidic environment of the
stomach and germinate in the intestine [30], which act
as a reservoir for C. difficile and can facilitate spread
among patients, as well as contribute to the high recur-
rence rates observed in CDI. The primary toxins pro-
duced by this bacterium are toxins A and B [31]. Toxins
A and B act as glucosyltransferases, promoting the acti-
vation of Rho GTPases leading to disorganization of the
cytoskeleton of the colonocyte, and eventual cell death
[32]. Since CDI is a toxin-mediated infection,
non-toxigenic C. difficile strains are non-pathogenic.
The respective roles and importance of toxins A and B
have been debated. Toxin A was thought to be the major
virulence factor for many years [33–35]. It is now estab-
lished that both toxins A and B are important for indu-
cing colonocyte death and colitis, and there is increasing
evidence pointing toward their role in CDI extra-intestinal
effects [36]. In addition to toxins A and B, some strains
Table 1 Grading of recommendations from Guyatt and colleagues [20, 21]
Grade of
recommendation
Clarity of risk/benefit Quality of supporting evidence Implications
1A
Strong
recommendation,
high-quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
RCTs without important limitations or
overwhelming evidence from observational studies
Strong recommendation, applies to
most patients in most circumstances
without reservation
1B
Strong
recommendation,
moderate-quality
evidence
Benefits clearly outweigh risk
and burdens, or vice versa
RCTs with important limitations (inconsistent
results, methodological flaws, indirect analyses or
imprecise conclusions) or exceptionally strong
evidence from observational studies
Strong recommendation, applies to
most patients in most circumstances
without reservation
1C
Strong
recommendation,
low-quality or very
low-quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
Observational studies or case series Strong recommendation but subject to
change when higher quality evidence
becomes available
2A
Weak
recommendation,
high-quality evidence
Benefits closely balanced
with risks and burden
RCTs without important limitations or
overwhelming evidence from observational studies
Weak recommendation, best action
may differ depending on the patient,
treatment circumstances, or social values
2B
Weak
recommendation,
moderate-quality
evidence
Benefits closely balanced
with risks and burden
RCTs with important limitations (inconsistent
results, methodological flaws, indirect or imprecise)
or exceptionally strong evidence from
observational studies
Weak recommendation, best action may
differ depending on the patient,
treatment circumstances, or social values
2C
Weak recommendation,
low-quality or very
low-quality evidence
Uncertainty in the estimates
of benefits, risks, and burden;
benefits, risk, and burden
may be closely balanced
Observational studies or case series Very weak recommendation; alternative
treatments may be equally reasonable
and merit consideration
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produce a third toxin known as binary toxin [37–41].
Binary toxin has an ADP-ribosyltransferase function,
which also leads to actin depolymerization [42, 43]. How-
ever, its pathogenetic role is still debated [44, 45].
Asymptomatic C. difficile colonization occurs when
C. difficile is detected in the absence of symptoms of
infection. Asymptomatic colonized individuals with no
clinical signs of CDI can still act as an infection reservoir
and transmit C. difficile to others [46, 47]. Asymptomatic
colonization with C. difficile may be a crucial factor in the
progression to CDI, as carriers of toxigenic strains may be
at a higher risk for the development of an infection
compared to non-colonized patients [48]. Other data
suggests that carriage of non-toxigenic C. difficile may
be protective against toxigenic ribotypes [49]. Estimates
of prevalence of asymptomatic C. difficile colonization
vary considerably between different patient groups.
Among healthy adults with no prior risk factors for
CDI, asymptomatic colonization prevalence varied
between 0 and 15% [50–56].
Risk factors
Risk factors for CDI may be divided into three general
categories: host factors (immune status, comorbidities),
exposure to C. difficile spores (hospitalizations, commu-
nity sources, long-term care facilities), and factors that
disrupt normal colonic microbiome (antibiotics, other
medications, surgery) [57].
Patient factors
Risk factors identified to date include age > 65 years, co-
morbidity or underlying conditions, inflammatory bowel
diseases, immunodeficiency (including human immuno-
deficiency virus infection), malnutrition, obesity, female
sex, and low serum albumin level [3, 58]. Patients with
comorbidities may have distinct characteristics of their
CDI, for example, in type 2 diabetes mellitus, patients
with CDI were younger, and sepsis and proton pump
inhibitors (PPIs) were important causes, but fever was
not a dominant feature [59].
The effects of prior appendectomy on the develop-
ment of C. difficile colitis have been debated [60]. A
review by Seretis et al. [61] of five studies conducted
retrospectively and published in 2014 reported that an
in situ appendix did not impact on the development of
CDI. In the retrospective analysis by Clanton et al. [62]
on 55 patients who underwent colectomy for CDI
between 2001 and 2011, a prior appendectomy was
noted in 24 of 55 patients (44%, 99% CI 0.280–0.606). In
another retrospective study of 507 patients [63], 13 of
119 patients (10.9%) with a previous appendectomy
required colectomy compared to 20 of 388 patients
(5.2%) with an intact appendix developing fulminant
infection and requiring colectomy and increased disease
severity, indicated by increased rates of colectomy,
occurred in the group with a history of appendectomy
(p = 0.03). A sub-group analysis of a large population-
based study published in 2013 [64] showed that appen-
dectomy was not associated with adverse outcomes in
CDI. Patients with appendectomy before CDI showed no
differences in risk factors, treatment, or outcomes
including treatment failure, development of severe or
severe-complicated CDI, or recurrence rates as compared
with patients without appendectomy. Larger prospective
studies are needed to assess the impact of prior appendec-
tomy on the development and severity of CDI.
Exposure to Clostridium difficile spores
Factors that increase risk of exposure to C. difficile
spores, such as increased duration of hospital stay,
increase the risk of CDI. A length of stay > 2 weeks has
been shown to be a risk factor for CDI [65]. Hospitals
with well-implemented infection prevention and control
measures are at lower risk of nosocomial CDI [66].
Normal flora disruption
The indigenous gut microbiota is a complex community
of microorganisms that populates the gastrointestinal
tract in a healthy person. This micro-ecosystem plays a
crucial role in protecting the intestines by providing
resistance to colonization and infection by pathogenic
organisms [67]. Gut microbiota has also immeasurable
effects on homeostasis of the host [68]. Under normal
conditions, the human gut microbiota may impede
pathogen colonization through general mechanisms such
as direct inhibition through bacteriocins, nutrient deple-
tion (consuming growth-limiting nutrients), or stimu-
lation of host immune defenses [57], though the exact
mechanism by which the microbiota protects against
CDI is unknown [69]. Disruption of the normal balance
of colonic microbiota as a consequence of antibiotic use
or other stressors is, however, of major importance [70].
Antibiotic exposure
Disruption of the normal gut flora allows C. difficile to
proliferate and produce toxins. In 1974, Tedesco et al.
published a prospective study of clindamycin-associated
colitis, which had become endemic in many hospitals
[71]. In 200 consecutive patients, administration of
clindamycin resulted in diarrhea in 21% and the incidence
of endoscopy-diagnosed pseudomembranous colitis was
10%. The study led to a search for an infectious cause of
colitis, and it identified C. difficile as the main causative
agent [72].
The risk of CDI is increased up to sixfold during anti-
biotic therapy and in the subsequent month afterwards
[73]. Although nearly all antibiotics have been associated
with CDI, clindamycin, third-generation cephalosporins,
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penicillins, and fluoroquinolones have traditionally
been considered to pose the greatest risk [74–80]. An
association between CDI and antimicrobial treatment
> 10 days has also been demonstrated [81, 82]. Anti-
biotics which have been less commonly associated
with CDI include macrolides, sulfonamides, and tetra-
cyclines [83]. Even very limited exposure, such as single-
dose surgical antibiotic prophylaxis, can increase patients
risk for both C. difficile colonization or infection [84–86].
Other medications
Exposure to gastric acid-suppressive medications, such
as histamine-2 blockers and PPIs, may be a potential risk
factor for development of CDI. Several studies have
suggested the association between use of stomach
acid-suppressive medications, primarily PPIs, and CDI
[87, 88]. In 2012, a systematic review of incident and
recurrent CDI in PPI users was published [89].
Forty-two observational studies (30 case-control, 12
cohort) totaling 313,000 participants were evaluated.
Despite the substantial statistical and clinical heteroge-
neity, the findings indicated a probable association
between PPI use and incident and recurrent CDI. This
risk was further increased by concomitant use of anti-
biotics and PPI. Other studies suggested that this asso-
ciation may be the result of confounding with the
underlying severity of illness and duration of hospital
stay [90]. Another meta-analysis about a plausible link
between CDI and PPIs was recently published [91].
Pooled analysis of 50 studies showed a significant asso-
ciation between PPI use and risk of developing CDI (odds
ratio [OR] = 1.26, 95% confidence interval (CI), 1.12–1.39)
as compared with non-users.
Even when compared to other gastric acid-suppressive
medication, a recent meta-analysis showed that the
use of PPI increased the risk of hospital-acquired CDI
(OR = 1.386, 95% CI 1.152–1.668) when compared to
H2-antagonist [92].
Given that PPIs are overprescribed in surgical settings,
consideration should be given to stop PPIs, when they are
not necessary, especially in patients at high risk of CDI.
Nasogastric tube
The risk of poor clinical outcomes of CDI in patients
with nasogastric tube (NGT) insertion is still controver-
sial. In order to assess the outcomes of CDI in patients
with NGT insertion, a systematic review and meta-ana-
lysis was recently published [93].
Eight observational studies were included in the
analysis to assess the association between NGT insertion
and risk of poor outcome of CDI. The pooled relative
risk (RR) of severe or complicated clinical outcomes of
CDI in patients with NGT insertion was 1.81 (95% CI
1.17–2.81).
This study demonstrated a statistically significant asso-
ciation between NGT insertion and risk of poor
outcomes of CDI. This finding may impact clinical
management and primary prevention of CDI. Avoidance
of unnecessary NGT uses would improve the clinical
outcomes of CDI.
Surgery
Reports have linked the development of CDI in surgical
patients to the widespread use of broad-spectrum anti-
biotics, and the increasing number of elderly and
immunocompromised patients undergoing surgical
interventions [17, 94, 95].
Abdelsattar et al. [18] prospectively identified post-
operative patients with laboratory-confirmed CDI
following general, vascular, or gynecological surgeries at
52 academic and community hospitals in the state of
Michigan, USA between July 2012 and September 2013.
The highest rates of CDI occurred after lower-extremity
amputation (2.6%), followed by bowel resection or repair
(0.9%) and gastric or esophageal surgeries (0.7%).
Gynecological and endocrine surgeries had the lowest
rates of CDI (0.1% and 0%, respectively). Multivariate
analysis identified increasing age, chronic immuno-
suppression, hypoalbuminemia (≤ 3.5 g/dL), and pre-
operative sepsis to be associated with postoperative CDI.
Zerey et al. [15] performed a 5-year retrospective ana-
lysis of the Agency for Healthcare Research and Quality’s
National Inpatient Sample Database representing a
stratified 20% sample of hospitals in the United States,
from 1999 to 2003. Emergency surgery was at higher risk
of CDI than elective surgery. Colectomy, small-bowel re-
section, and gastric resection were associated with the
highest risk of CDI. Patients undergoing cholecystec-
tomy and appendectomy had the lowest risk.
In 2010, Rodriguez et al. [96] published a retrospective
analysis of all general surgery in patients admitted to a
large tertiary referral general surgical unit in the UK,
between March 2005 and May 2007. Multivariate ana-
lysis identified malignancy, gastrointestinal disease,
anemia, respiratory disease, cardiovascular disease,
diabetes mellitus, gastrointestinal surgery, and age as
independently associated with C. difficile.
To assess risk factors for CDI on a surgical ward, in
2012 Kim et al. conducted a retrospective chart review
of all patients admitted between January 2010 and July
2011 [97]. The rate of CDI was 0.4% (19/4720 patients).
Multivariate analysis showed that colectomy and hospital
stays > 10 days were the main risk factors for CDI in the
surgical ward.
Using the Japanese Diagnosis Procedure Combination
inpatient database, Yasunaga et al. [98] analyzed factors
associated with CDI incidence and outcomes following
digestive tract surgery. Of 143,652 patients undergoing
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digestive tract surgery, CDI was identified in 409 (0.28%)
patients. High mortality, long hospital stay, and high
costs were associated with post-surgical CDI.
Colorectal surgery is a documented risk factor for CDI
[99, 100]. Damle et al. [101] published a retrospective
analysis of patients who developed CDI following colo-
rectal resection. The authors identified adult patients
undergoing colorectal surgery between 2008 and 2012
from the US University Health System Consortium data-
base. A total of 84,648 patients met study inclusion
criteria. CDI occurred in 1266 (1.5%) patients. The
strongest predictors of CDI were emergency procedure,
inflammatory bowel disease, and severity of illness score.
CDI was associated with a higher rate of complications,
intensive care unit (ICU) admission, longer preoperative
inpatient stay, 30-day readmission rate, and death within
30 days compared to non-CDI patients.
Recently, a retrospective colectomy database review of
the 2015 American College of Surgeons National Surgi-
cal Quality Improvement Project [102] demonstrated
that stoma reversal (OR = 2.701, 95% CI 1.966–3.711;
p < 0.001), smoking (OR = 1.520, 95% CI 1.063–2.174;
p = 0.022), steroids (OR = 1.677, 95% CI 1.005–2.779;
p = 0.048), and disseminated cancer (OR = 2.312, 95%
CI 1.437–3.719; p = 0.001) were associated with CDI
in the 30-day postoperative period.
In 2008, Lumpkins et al. published a retrospective
observational study on the incidence of CDI in the cri-
tically injured trauma population [103]. Five hundred
eighty-one consecutive critically injured trauma patients
were followed prospectively for development of CDI,
diagnosed by toxin assay. Among 581 patients, 19 cases
of CDI were diagnosed (3.3%). ICU length of stay,
duration of mechanical ventilation, and hospital length
of stay were associated with CDI. The diagnosis was
documented with a median delay of 17 days after
admission. Fourteen patients (74%) had received anti-
biotics for confirmed or suspected infection prior to
CDI; 4 patients (21%) received only intraoperative
prophylaxis, and 1 patient had no antibiotic exposure.
Obesity and bariatric surgery
Obesity as a risk factor for CDI has been debated.
Several reports have recently proposed obesity as a novel
risk factor for CDI [104–106]. On the other hand, Punni
et al. [107], in a case-control study, showed that obesity
is not a risk factor for CDI. Importantly, body mass > 35
index has been shown to be an independent risk factor
for CDI [108].
To investigate the impact of the two most common
bariatric surgeries on CDI, Roux-en-Y gastric bypass
(RYGB), and vertical sleeve gastrectomy (VSG), a retro-
spective cohort study was recently published [109]. CDI
rates were higher after RYGB than VSG in the first
30 days (OR = 2.10; 95% CI, 1.05–4.20) with a similar
but not significant trend within 31–120 days.
Knowledge about the link between obesity, bariatric
surgery, and CDI is still evolving. Further studies are
needed to reveal the exact mechanisms underlying this
association. At this stage, we suggest high suspicion
for CDI when managing patients with obesity and
undergoing bariatric surgery.
Inflammatory bowel disease
Patients with inflammatory bowel disease (IBD) retain
an increased risk of developing CDI, along with worse
outcomes, higher rates of colectomy, and higher rates of
recurrence [110–115].
Patients with IBD also appear to have higher rates of
asymptomatic carriage of C. difficile [116]. These patients
commonly receive various types of immunosuppressive
drugs including steroids which have been found to
increase the risk of CDI. In addition, they have a different
microbiota compared to healthy subjects [117, 118].
A recent retrospective study evaluated the impact of
CDI on in-hospital outcomes among adults with IBD
hospitalized in the USA [119]. Using the 2007–2013
Nationwide Inpatient Sample, hospitalizations among
US adults with Crohn’s disease (CD), ulcerative colitis
(UC), and CDI were identified using ICD-9 coding.
Hospital charges, hospital length of stay (LOS), and
in-hospital mortality was stratified by CD and UC and
compared. Predictors of hospital charges, LOS, and in-hos-
pital mortality were evaluated with multivariate regres-
sion models and were adjusted for age, sex, race/
ethnicity, year, insurance status, hospital characteristics,
and CDI. Among 224,500 IBD hospitalizations (174,629
CD and 49,871 UC), overall prevalence of CDI was
1.22% in CD and 3.41% in UC. On multivariate linear
regression, CDI was associated with longer LOS among
CD (coefficient: 5.30, 95% CI 4.61–5.99; p < 0.001) and
UC (coefficient 4.08, 95% CI 3.54–4.62; p < 0.001).
Higher hospital charges associated with CDI were seen
among CD (coefficient $35,720, 95% CI $30,041–$41,399;
p < 0.001) and UC (coefficient $26,009, 95% CI
$20,970–$31,046; p < 0.001). CDI among IBD was asso-
ciated with almost threefold greater risk of in-hospital
mortality.
The clinical presentation of an IBD exacerbation and
CDI often is indistinguishable and requires a high index
of suspicion for adequate treatment [6]. As the symp-
toms of CDI and an exacerbation of IBD (diarrhea,
abdominal pain, fever, and leukocytosis) overlap, the
diagnosis of CDI may be delayed [120]. In addition, in
IBD patients with ileostomies, the development of acute
enteritis manifested as an increase in ileostomy output,
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nausea, fever, and leukocytosis may also indicate CDI.
The same is true for pouchitis, which presents as an in-
crease in the number of stools per day [121]. In one
study, 10.7% of patients with ileal pouch anal anasto-
mosis, presenting with pouchitis, were found to have
CDI [122].
Due to high rates of asymptomatic colonization by
C. difficile in patients with IBD, only patients with
increased diarrhea or new symptoms potentially due
to CDI should be tested for C. difficile toxin. Typical
findings of CDI on colonoscopy are often absent in
patients with IBD (0–13% of cases) [123] which may
be attributed to a weakened inflammatory response.
There is no evidence that one antibiotic regimen is
better than another for the treatment of CDI in IBD
patients. In a survey of North American gastroen-
terologists, there was no agreement on combination
of antibiotics and immunomodulators in patients with
an IBD flare and CDI [124]. The American College of
Gastroenterology recommended with low-quality suppor-
ting evidence, that ongoing immunosuppression can be
maintained in patients with CDI and that escalation of
immunosuppression should be avoided [125].
An expert review to synthesize the existing evidence
on the management of CDI in patients with underlying
inflammatory bowel disease was published in 2017.
The review suggested six simple advices of best
practice [126].
Physicians should remain alert to the possibility of
CDI in a patient with an IBD exacerbation to ensure
rapid diagnosis and treatment. Early surgical con-
sultation is also key for improving outcomes of patients
with severe disease. Colectomy with preservation of the
rectum may need to be considered for severely ill IBD
patients with CDI.
Immunocompromised patients
The rate of CDI is increased in solid organ transplant
recipients due to ongoing immunosuppression and anti-
biotic use [127].
It has also been reported that cancer patients have a
higher risk compared with non-cancer patients [128] due
to chemotherapy causing immunosuppression [129, 130].
Patients with HIV/AIDS are also at high risks of being
infected with C. difficile too. The risk is stronger in
those with low absolute CD4 T cell counts or those who
meet clinical criteria for AIDS [131].
The increased risk may be partially attributed to
frequent hospitalization, exposure to antibiotics, and
antibiotic prophylaxis for opportunistic infections, but
HIV-related alterations in fecal microbiota, gut mucosal
integrity, and humoral and cell-mediated immunity may
also likely play a role [132].
Risk factors for community-acquired C. difficile
infection
Although predominantly associated with the inpatient
health care population, CDI originating in the commu-
nity has been increasingly reported. The predominant
C. difficile ribotypes isolated in the hospital setting cor-
respond with those isolated in the community, suggest-
ing that transmission between these two settings is
occurring [133].
In 2011, an estimated 159,000 community-associated
CDI (CA-CDI) occurred in the USA, representing 35%
of the total CDI burden [134].
Risk factors may include increasing outpatient antibiotic
prescriptions, acid-suppression medications, asymp-
tomatic carriers in the community, and food or water
contamination [135]. A sub-group analysis of a
population-based epidemiological study of CDI in
Olmsted County, Minnesota in 1991–2005 [136], iden-
tified 157 CA-CDI cases (75% women), with a median
age of 50 years. Among them, 40% required hospitalization,
20% had severe, and 4.4% severe-complicated infec-
tion, while 20% had treatment failure and 28% had
recurrent CDI.
A case-control study from ten US sites from October
2014 to March 2015 analyzed risk factors for CA-CDI
[137]. Case patients were defined as persons aged
≥ 18 years with a positive C. difficile specimen collected as
an outpatient or within 3 days of hospitalization who had
no admission to a health care facility in the prior 12 weeks
and no prior CDI diagnosis. Each case patient was
matched to one control (persons without CDI). Parti-
cipants were interviewed about relevant exposures; multi-
variate conditional logistic regression was performed.
More case patients than controls had prior outpatient
health care (82.1% vs. 57.9%; p < 0.0001) and antibiotic
(62.2% vs. 10.3%; p < 0.0001) exposures. In multivariate
analysis, antibiotic exposure—that is, cephalosporin
(adjusted matched odds ratio [AmOR], 19.02; 95% CI
1.13–321.39), clindamycin (AmOR, 35.31; 95% CI
4.01–311.14), fluoroquinolone (AmOR, 30.71; 95% CI
2.77–340.05), and beta-lactam and/or beta-lactamase
inhibitor combination (AmOR, 9.87; 95% CI 2.76–
340.05)—emergency department visit (AmOR, 17.37;
95% CI 1.99–151.22), white race (AmOR 7.67; 95% CI
2.34–25.20), cardiac disease (AmOR, 4.87; 95% CI
1.20–19.80), chronic kidney disease (AmOR, 12.12;
95% CI 1.24–118.89), and IBD (AmOR, 5.13; 95% CI
1.27–20.79) were associated with CA-CDI.
A systematic review and meta-analysis investigated
the association between medications and comorbidities
with CA-CDI [138]. Twelve publications (n = 56,776
patients) met inclusion criteria. Antimicrobial (OR = 6.18,
95% CI 3.80–10.04) and corticosteroid (OR = 1.81, 95% CI
1.15–2.84) exposure were associated with increased risk of
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CA-CDI. Among the comorbidities, IBD (OR = 3.72, 95%
CI 1.52–9.12), renal failure (OR = 2.64; 95% CI 1.23–5.68),
hematologic malignancy (OR = 1.75; 95% CI 1.02–5.68),
and diabetes mellitus (OR = 1.15; 95% CI 1.05–1.27) were
associated with CA-CDI. Antimicrobial exposure was
associated with a higher risk of CA-CDI in the USA,
whereas PPI exposure was associated with a higher risk in
Europe. The risk of CA-CDI associated with antimicrobial
exposure greatly increased in adults older than 65 years.
Risk factors for recurrent CDI
Recurrent CDI (RCDI) can be defined as reappearance of
symptoms within eight weeks following the completion of a
course of therapy with complete resolution of symptoms.
The key to preventing recurrent infection is identifying
those patients at the greatest risk [139].
In a meta-analysis, Garey et al. [140] found that con-
tinued use of non-C. difficile antibiotics after diagnosis
of CDI (OR = 4.23; 95% CI 2.10–8.55; p < 0.001), con-
comitant receipt of antacid medications (OR = 2.15; 95%
CI 1.13–4.08; p = 0.019), and older age (OR = 1.62; 95%
CI 1.11–2.36; p = 0.0012) were associated with increased
risk of recurrent CDI. Other factors identified in individ-
ual studies include age, hospital exposure, comorbid
conditions, severe underlying illness, hypoalbuminemia,
impaired humoral immunity, poor quality of life, disease
severity, and previous recurrent CDI [141–144].
In order to evaluate current evidence of risk factors
for recurrent CDI, a systematic review and meta-analysis
[145] analyzed 33 studies (18,530 patients). The most
frequent independent risk factors for recurrent CDI were
age ≥ 65 years (RR = 1.63, 95% CI 1.24–2.14; p = 0.0005),
additional antibiotics during follow-up (RR = 1.76; 95%
CI 1.52–2.05; p < 0.001), use of PPIs (RR = 1.58; 95% CI
1.13–2.21; p = 0.008), and renal failure (RR = 1.59; 95%
CI 1.14–2.23; p = 0.007). The risk was also increased in
patients previously on fluoroquinolones (RR = 1.42; 95%
CI 1.28–1.57; p < 0.001).
Clinical manifestations
The spectrum of symptomatic CDI ranges from mild
diarrhea to severe disease or fulminant colitis and as
many as 30% of patients may develop recurrent CDI
[146, 147].
Though diarrhea is the hallmark symptom of CDI, it
may not be present initially, possibly due to colonic
dysmotility either from previous underlying conditions
or possibly from the disease process itself [148].
This is especially important in surgical patients who
may have a concomitant ileus. Therefore, in surgical
patients, it is important to have a high index of suspicion
for the development of CDI.
Mild-moderate CDI
Diarrhea may be accompanied by mild abdominal pain
and cramps and if prolonged may result in altered
electrolyte balance and dehydration. When this occurs
in patients with severe comorbidity, particularly after
surgery, non-severe CDI may increase morbidity
significantly [149].
Severe CDI
Severe CDI is associated with increased abdominal
cramping and pain as well as systemic features such as
fever, leukocytosis, and hypoalbuminemia. The absence
of diarrhea may signal a progression to fulminant infec-
tion [150]. Though a wide variety of severity predictors
for severe CDI has been described [151–156], inter-
national consensus for the definition of severe CDI is
lacking [6, 7].
A systematic review identifying risk factors for adverse
outcomes of CDI was published by Abou Chakra et al.
in 2012 [154]. Except for leukocytosis, albumin, and age,
there was much heterogeneity in the data and most
studies were limited by small sample sizes.
To investigate the prognostic value of fever,
leukocytosis, and renal failure, in 2012 Bauer et al. [153]
analyzed the database of two randomized controlled
trials, which contained information on 1105 patients
with CDI. They found that both leucocytosis and renal
failure were useful predictors of in severe CDI. Miller
et al. [155] in 2013 subsequently published an analysis
of the same two clinical therapeutic trials to validate a
categorization system to stratify CDI patients into se-
vere or mild-moderate groups. A combination of five
simple and commonly available clinical and laboratory
variables (ATLAS) measured at the time of CDI diagno-
sis were able to accurately predict treatment response
to CDI therapy. The ATLAS criteria included age, treat-
ment with systemic antibiotics, leucocyte count, serum
albumin, and serum creatinine levels.
Any of the following may be predictors of severe CDI:
 WBC > 15 × 109/L
 Rise in serum creatinine level (≥ 133 μM/L or ≥ 1.5
times premorbid level)
 Temperature > 38.5 °C
 Albumin < 2.5 g/dL
It has been recently demonstrated that human serum
albumin is capable to bind C. difficile toxin A and B thus
impairing their internalization into host cells; this could
partially explain the increased CDI severity experienced
by hypoalbuminemic patients [157].
The progression to fulminant C. difficile colitis is rela-
tively infrequent [158] (1–3% of all CDI) though morta-
lity in this group of patients remains high due to the
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development of toxic megacolon with colonic perfo-
ration, peritonitis, and septic shock and subsequent
organ dysfunction. Systemic symptoms may not merely
result from toxin-induced inflammatory mediators
released locally in the colon but likely to the toxins
spread into the bloodstream [36, 159, 160].
Studies have demonstrated a significant rise in the
number of cases of fulminant colitis associated with
multiple organ failure and increased mortality in recent
years associated with the hypervirulent 027 strain of
C. difficile [161, 162]. Early diagnosis and treatment is
therefore important in reducing the mortality associated
with fulminant colitis. Patients who present organ failure
including increased serum lactate or vasopressor require-
ments should be assessed immediately with regard to early
operative intervention [162].
Recurrent CDI
Recurrence of symptoms after initial therapy for
C. difficile develops in 10–30% of cases, and presents a
clinical challenge [144, 163–167]. For a patient with
1–2 previous episodes, the risk of further recurrences
is 40–65%.
Recurrences are associated with an impaired immune
response to C. difficile toxins and/or alteration of the
colonic microbiota.
RCDI may be either a consequence of germinating
resident spores remaining in the colon after antibiotic
treatment has stopped, or re-infection from an environ-
mental source.
Even though consensus regarding factors associated
with CDI recurrence is not universal, algorithms have
been developed to predict CDI recurrence with good
sensitivity [168].
Ultimately, distinction between recurrence and re-
infection can only be achieved if the strain of C. difficile
is “typed” using molecular epidemiology [169].
Recurrent episodes are less severe compared to initial
episodes: in a Canadian study, the authors reported a
decline in the proportion of severe cases according to
the number of recurrent episodes (47% for initial
episodes, 31% for first recurrences, 25% for second, and
17% for third) [170].
Additional significant consequences of CDI
Patients who develop CDI have increased hospital
length-of-stay, higher medical care costs, more hospital
re-admissions, and higher mortality [171–173]. These
consequences are also found in surgical patients with CDI.
In the Zerey et al. analysis [15], CDI was an indepen-
dent predictor of increased length of stay, which in-
creased by 16.0 days (95% CI 15.6–16.4 days; p < 0.0001).
Total charges increased by $77,483 (95% CI $75,174,
$79,793; p < 0.0001), and there was a 3.4-fold increase in
the mortality rate (95% CI 3.02–3.77; p < 0.0001) com-
pared with patients who without C. difficile infection.
In the Abdelsattar et al. study [18], postoperative CDI
was independently associated with increased length of
stay (mean, 13.7 days vs. 4.5 days), emergency depart-
ment presentations (18.9 vs. 9.1%), and readmissions
(38.9% vs. 7.2%, all p < 0.001).
Data from Nationwide Inpatient Sample database in
2011 of patients who underwent vascular surgery [174]
showed that in patients who had experienced CDI, the
median length of stay was 15 days (IQR 9, 25 days) com-
pared to 8.3 days for matched patients without CDI,
in-hospital mortality 9.1% (compared to 5.0%), and
$13,471 extra cost per hospitalization. The estimated
cost associated with CDI in vascular surgery in the USA
was about $98 million in 2011. Similarly, data from the
National Inpatient Sample in patients undergoing
lumbar surgery found that CDI increased length of stay
by 8 days, hospital costs by 2-fold, and increased
inpatient mortality by 36-fold [175].
Higher mortality was also observed for liver transplant
recipients (from 2000 to 2010) at a Detroit hospital [176].
The ACS-NSQIP database from 2005 to 2010 was
used by Lee et al. to study emergently performed open
colectomies for a primary diagnosis of C. difficile colitis
in the USA [177]. The overall mortality was 33%
(111/335).
A study was performed to quantify additional hospital
stay attributable to CDI in four European countries, by
analyzing nationwide hospital-episode data [5]. Patients
in England had the longest additional hospital stay
attributable to CDI at 16.09 days, followed by Germany
at 15.47 days, Spain at 13.56 days, and The Netherlands
at 12.58 days. Propensity score matching indicated a
higher attributable length of stay of 32.42 days in
England, 15.31 days in Spain, and 18.64 days in the
Netherlands. Outputs from this study consistently de-
monstrate that in European countries, in patients whose
hospitalization is complicated by CDI, the infection
causes a statistically significant increase in hospital
length of stay.
Recommendations for the management of CDI
Infection prevention and control
An infection control “bundle” strategy should be used to
successfully control CDI outbreaks. The “bundle”
approach should include multifaceted interventions
including antibiotic stewardship, hand hygiene, isolation
measures, and environmental disinfection.
1. Proper antibiotic stewardship in both selecting an
appropriate antibiotic and optimizing its dose and
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duration to prevent and cure an infection may
prevent the emergence of C. difficile
(Recommendation 1 B).
As CDI is thought to follow disruption of normal bac-
terial flora of the colon, a consequence of antibiotic use
[178], it is logical that antibiotic stewardship programs
may be useful in preventing CDI [179]. Good antibiotic
stewardship involves ensuring appropriate antibiotic
choices and optimizing antibiotic doses and duration of
treatment to prevent and cure an infection while mini-
mizing toxicity and conditions conducive to the develop-
ment of CDI.
In order to estimate the effectiveness and safety of inter-
ventions to improve antibiotic prescribing practices in
hospital inpatients in 2017, a systematic review including
221 studies (58 RCTs, and 163 NRS) was published [180].
The results showed a very low level of evidence regarding
the effect of interventions to reduce CDI (median − 48.6%,
interquartile range − 80.7% to − 19.2%; seven studies).
Another systematic review and meta-analysis quanti-
fied the effect of both persuasive (education and
guidance) and restrictive (approval required, removal)
antimicrobial stewardship programs for CDI [179]. A
significant protective role (overall RR = 0.48, 95% CI
0.38–0.62) was found, with the strongest evidence for
restrictive program and those with the longest duration.
Cephalosporins and quinolones reduction should be an
important target for stewardship programs, with a signifi-
cant expected impact on the incidence of CDI [181, 182].
2. C. difficile carriers should be placed in contact
(enteric) precautions (Recommendation 1 B). Even
if further studies are warranted to establish the
benefit of screening and the efficacy of infection
control measures for asymptomatic carriers.
Prompt identification of patients with CDI is essential,
so that appropriate isolation precautions can be put into
effect [183].
This is particularly important in reducing environmen-
tal contamination as spores can survive for months in
the environment [184], despite regular use of environ-
mental cleaning agents.
It is important to place patients suspected of having
CDI on contact precautions before diagnostic laboratory
test confirmation if there is a lag before test results are
available [185].
Contact (enteric) precautions in patients with CDI
should be maintained until the resolution of diarrhea,
which is demonstrated by passage of formed stool for at
least 48 h. There are no studies demonstrating that
further extension of contact precautions results in
reductions in CDI incidence.
C. difficile carriers should be placed in a private room
[186] with en-suite hand washing and toilet facilities. If a
private room is not available, known CDI patients may
be cohorted in the same area [187] though the theore-
tical risk of transfection with different strains exists. This
is supported by a retrospective cohort of 2859 patients
published by Chang et al. [188]. Non-infected patients
who were roommates or neighbors of a patient with CDI
were at higher risk of nosocomial acquisition of CDI
(RR 3.94; 95% CI 1.27–12.24).
Recently, there has been growing interest in asymptom-
atic carriage/colonization of C. difficile since asymptom-
atic carriers are considered a reservoir for C. difficile.
Colonization by toxigenic C. difficile strain seems to be
associated with increased risk of progressing to CDI.
Zacharioudakis et al. [48] showed that carriers of toxigenic
strains are at a higher risk for the development of an
infection compared to non-colonized patients. On the
other hand, patients colonized by non-toxigenic strains
may be even protected from developing CDI [189]. Con-
version of a non-toxigenic strain to a toxin producer by
horizontal gene transfer makes the risk assessment of
colonization really challenging [190]. More data are
needed to assess the precise role of the microbiota and the
conditions allowing progression from asymptomatic
colonization to CDI, in particular the recognition of the
mechanism which may trigger toxin production. Based
on current data, screening for asymptomatic carriers
and an eradication of C. difficile is not indicated be-
cause C. difficile colonization is not believed to be a
direct independent precursor for CDI. C. difficile
asymptomatic carriers may also play a role in spore dis-
semination in the hospital and many cases of CDI are
thought to be attributable to cross-contamination from
asymptomatic carriers. Curry et al. [191] examined pa-
tients for C. difficile colonization and found that 29% of
CDIs were linked to asymptomatic C. difficile carriers.
Asymptomatic carriers who are colonized at admission
appear to contribute to sustaining C. difficile transmission
in the ward by the shedding of spores to the environment.
The frequency of environmental contamination depends
on the C. difficile status of the patient—34% of rooms of
patients with asymptomatic colonization and 49% of
rooms of CDI patients were found to be contaminated
with C. difficile [192]. Infection control measures for
asymptomatic carriers may be effective by limiting con-
tamination of the hospital environment and health care
workers’ hands, as well as by preventing direct patient-
to-patient transmission. Longtin et al. [185] reported that
screening of C. difficile colonization at hospital admission
and contact precautions were associated with a significant
decrease in the HA-CDI incidence rate (6.9 per 10,000
patient-days in the pre-intervention period vs. 3.0 per
10,000 patient-days during the intervention period;
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p < 0.001). This study provides the most convincing
evidence to date for the significant effect of isolating
asymptomatic carriers.
3. Hand hygiene with soap and water is the
cornerstone of the prevention of C. difficile
infection. Hand hygiene, contact precautions, and
good cleaning and disinfection of patient care
equipment and the environment should be used by
all health-care workers in contact with any patient
with known or suspected CDI (Recommendation 1 B).
In a health-care setting, transmission of C. difficile
spores occurs primarily via the contaminated hands of
health-care workers, but contact with a contaminated
environment, contaminated utensils or medical devices
has also been implicated. Hand hygiene with soap and
water and the use of contact precautions along with
good cleaning and disinfection of the environment and
patient equipment should be used by all health-care
workers in contact with any patient with known or
suspected CDI. Hand hygiene is a cornerstone of pre-
vention of nosocomial infections, including infection due
to C. difficile. Alcohol-based hand sanitizers are highly
effective against non-spore-forming organisms, but they
do not kill C. difficile spores or remove C. difficile from
the hands [193].
Though disposable glove use during care of a patient
with CDI may be effective in preventing the transmis-
sion of C. difficile, these must be removed at the point
of use and the hands should then be thoroughly decon-
taminated with soap and water.
For environmental cleaning, disinfection with sodium
hypochlorite solutions are usually recommended in patient
areas where C. difficile transmission is ongoing [194].
In 2016, a cross-sectional study was conducted in a
tertiary care hospital to analyze the impact of location of
sinks on hand washing compliance after caring for
patients with CDI. Healthcare workers’ hand washing
compliance was low, and a poor access to sinks was
associated with decreased hand washing compliance [195].
Environmental decontamination of clinical areas,
ideally using hypochlorite agents or a sporicidal product,
is recommended; however, in practice, compliance with
cleaning protocols is often suboptimal.
In 2017, a qualitative systematic review including 46
studies investigated the impact of specific interventions
on CDI rates in acute-care hospitals. The most effective
interventions, resulting in a 45% to 85% reduction in
CDI, included daily to twice daily disinfection of
high-touch surfaces (including bed rails) and terminal
cleaning of patient rooms with chlorine-based products.
Chlorhexidine bathing and intensified hand-hygiene
practices were not effective for reducing CDI rates [196].
Newer alternatives for environmental decontamination
have been introduced, notably hydrogen peroxide vapor
(HPV) and, more recently, UV decontamination [197].
In a study conducted by McCord et al., breakpoint
time series analysis indicated a significant reduction
(p < 0.001) in the CDI rate at the time when HPV dis-
infection was implemented, resulting in a reduction in the
CDI rate from 1.0 to 0.4 cases per 1000 patient-days in the
24 months before HPV usage compared with the first
24 months of HPV usage [198].
Recently, a systematic literature review and meta-analysis
on the impact of no-touch disinfection methods to
decrease HAIs was performed [199]. Statistically significant
reduction in CDI (RR = 0.64; 95% CI 0.49–0.84) was
observed using UV light no-touch disinfection technology.
Important to point out that the new no-touch methods for
room disinfection supplement, but do not replace, daily
cleaning [200].
The European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) study group for C. difficile
(ESGCD) recently published a set of guidelines regarding
measures for prevention of C. difficile infection in acute
healthcare settings [201]. According to the committee, it
is recommended:
 To use personal protective equipment (gloves and
gowns/disposable aprons) to decrease transmission
of C. difficile or incidence of CDI
 To use contact precautions to decrease the
transmission of C. difficile and reduce the incidence
of CDI
 To introduce daily environmental sporicidal
disinfection and terminal disinfection of rooms of
patients with CDI to decrease the transmission of
CDI
 To perform surveillance of CDI in combination with
timely feedback of infection rates on both the
hospital and ward level
 To implement restriction protocols of antibiotic
agents/classes (effective in reducing CDI rates)
 To implement protocols to reduce the duration of
antibiotic therapy (effective in reducing CDI rates)
 Educate healthcare workers on prevention of CDI to
enhance their knowledge and skills on prevention
strategies
It is not recommended:
 To screen for C. difficile to identify colonized/carrier
patients as a way of altering the risk of developing
CDI in either colonized subjects or other patients
and thus reducing CDI rates
 To screen health care workers for C. difficile gut
colonization as a routine control measure for CDI
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Diagnosis
4. The diagnosis of CDI should be based on clinical
signs and symptoms in combination with laboratory
tests. Stool testing should only be performed on
diarrheal stools from at-risk patients with clinically
significant diarrhea (≥ 3 loose stools in 24 h) with
no obvious alternative explanation (Recommenda-
tion 1 C).
5. For patients with ileus who may be unable to
produce stool specimens, polymerase chain reaction
testing of perirectal swabs provides an acceptable
alternative to stool specimen analysis
(Recommendation 2B).
Typing is useful to differentiate C. difficile strains and
to obtain epidemiological information. Different typing
methods for C. difficile currently available are: restriction
endonuclease analysis (REA), pulsed-field gel electro-
phoresis (PFGE), multi-locus sequence typing (MLST),
repetitive-element PCR typing, toxin-typing, multi-locus
variable-number tandem-repeat analysis (MLVA), and
PCR-ribotyping [201]. C. difficile strains with increased
virulence traits (hypervirulent) have been described in
the last 15 years. In particular, PCR-ribotype 027, also
known as North American pulsed-field gel electrophor-
esis type 1 (NAP1) or restriction endonuclease analysis
group BI, has been associated with increased disease
severity, recurrence, and significant mortality [202].
The diagnosis of C. difficile infection should be sus-
pected in patients with acute diarrhea (≥ 3 loose stools
in 24 h) with no obvious alternative explanation (such as
laxative use), particularly in the setting of relevant risk
factors (including recent antibiotic use, hospitalization,
and advanced age).
Prompt and precise diagnosis is important for the
effective management of CDI. An accurate diagnosis of
CDI requires both clinical symptoms and a positive
laboratory test.
Early identification of CDI allows early treatment and
can potentially improve outcomes. Rapid isolation of
infected patients is important in controlling the trans-
mission of C. difficile [203].
The diagnosis of CDI is based on the presence of a
clinical picture compatible with CDI and microbiological
evidence of free toxin and/or the demonstration of toxi-
genic C. difficile in a diarrhea stool sample [203]. Cli-
nical features include diarrhea (defined as by passage of
three or more unformed stools in 24 h), abdominal pain
and cramps, abdominal distension, ileus (signs of
severely disturbed bowel function), and toxic megacolon.
Since C. difficile can colonize the intestinal tract of
healthy individuals, diagnostic testing for CDI should be
performed only on diarrheic stools from symptomatic
patients. Testing of formed stool can result in false positive
tests, which may result in unnecessary antibiotic therapy.
One limitation of the reliance on stool specimens
involves patients with suspected severe CDI complicated
by ileus as those patients may be unable to produce
specimens for testing. For those patients, testing of peri-
rectal swabs may be an accurate and efficient method to
detect toxigenic C. difficile. In 2012, Kundrapu et al.
[204] described the results of a prospective study of 139
patients being tested for C. difficile infection by polyme-
rase chain reaction. The sensitivity, specificity, positive
predictive value, and negative predictive value of testing
perirectal swabs were 95.7%, 100%, 100%, and 99.1%,
respectively. The authors concluded that for selected
patients, perirectal swabs provided an acceptable alter-
native to stool specimen analysis.
Clinical context such as a history of recent antibiotic
administration and/or residence in hospital are useful in
selecting patients for testing. Other signs such as fever,
abdominal pain, leukocytosis, in combination with other
laboratory tests (e.g., creatinine and serum lactate) are
useful for defining the severity of infection.
6. Nucleic acid amplification tests (NAAT) for C.
difficile toxin genes appear to be sensitive and
specific and may be used as a standard
diagnostic test for CDI. NAAT as single-step
algorithm can increase detection of asymptomatic
colonization, therefore it should be performed in
patients with high suspicion for CDI or included in
two-step algorithm starting with toxin-EIA
(Recommendation 1 B).
7. Glutamate dehydrogenase (GDH) screening tests
for C. difficile are sensitive but do not differentiate
between toxigenic and non-toxigenic strains. They
may be used in association with toxin A/B enzyme
immunoassays (EIA) testing. Algorithms including
screening with an EIA for GDH followed by a toxin
assay may be suggested (Recommendation 1 B).
8. EIA for toxin A/B is fast and inexpensive and has
high specificity but it is not recommended alone
due to its relatively low sensitivity
(Recommendation 1 B).
9. C. difficile culture is relatively slow but sensitive. It
is rarely performed today as a routine diagnostic
test. C. difficile culture is recommended for
subsequent epidemiological typing and
characterization of strains (Recommendation 1 C).
10. Repeat testing after a first negative sample during
the same diarrheal episode may be useful only in
selected cases with ongoing clinical suspicion
during an epidemic situation or in cases with high
clinical suspicion during endemic situations
(Recommendation 1 C).
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The best standard laboratory test for diagnosis of CDI
has not been clearly established [205].
Currently, there is no single stool test that can be
relied upon as the reference standard for the diagnosis of
CDI. Several methods are suggested for the diagnosis of
CDI, including toxinogenic culture (TC), cell cytotoxicity
neutralization assay (CCNA), enzyme immunoassays
(EIA) for toxins A, B, and/or glutamate dehydrogenase
(GDH), and nucleic acid amplification tests (NAATs).
In the past, TC was accepted by many microbiologists
as the method of choice for diagnosis of CDI. The
procedure includes stool culture for C. difficile on a
selective differential medium (cycloserine, cefoxitin,
fructose agar, or CCFA) and an assay to test the colonies
for the ability to produce toxins. Despite TC is consi-
dered the gold standard method, there are significant
issues with TC including slow turnaround time and its
inability to detect the presence of toxins in stool. This
may also lead to false positive results as up to 7% of
asymptomatic hospitalized patients may be colonized
with toxigenic C. difficile [206].
C. difficile culture is also necessary for subsequent
epidemiological typing and characterization of strains.
The EIA for toxin A/B has been adopted by most
clinical laboratories because it is fast, convenient, and
inexpensive [207]. However, studies have shown that
sensitivity can be low. Toxin A + B EIA tests have a
described sensitivity of 32–98% and a specificity of
84–100% [208].
GDH is an enzyme produced by C. difficile in relatively
large amounts compared with toxins A and B [209, 210].
A positive GDH assay only documents the presence of
C. difficile but it does not discriminate between toxigenic
and non-toxigenic strains (about 20% of the C. difficile
population). Therefore, a second test for toxin produc-
tion is necessary for confirmation. GDH screening tests
for C. difficile used in association to toxin A + B EIA
testing gives an accurate test result quickly [207, 208]
even if the sensitivity of such strategy is lower than
NAATs.
The use of NAATs for the detection of C. difficile from
diarrheal stool specimens was documented in the early
1990s. NAATs possess a series of advantages such as
excellent sensitivity and specificity, low complexity,
simplified reporting, reduced need for repeat testing,
and improved turnaround time [209–212].
In particular, some NAATs such as multiplex NAATs
can simultaneously detect C. difficile strains and toxin
encoding genes from stool samples [213].
There are several commercially available NAATs,
including a real-time PCR (RT-PCR) assay and loop-me-
diated isothermal amplification (LAMP) assay, both of
which have an overall high analytical sensitivity (80–
100%) and specificity (87–99%).
However, although NAATs have a high sensitivity and
specificity, not all laboratories routinely perform this
assay [214]. Moreover, some limitations have been asso-
ciated with NAATs [215].
Although NAAT methods are considered superior to
other methods of diagnosing CDI, this testing strategy is
unable to accurately distinguish between C. difficile
colonization and active disease, which may result in both
over diagnosis and overtreatment of CDI, delaying re-
cognition of other causes of diarrheal illness/outbreaks,
and resulting in unnecessary exposure to antibiotics
used to treat CDI.
A current topic of debate is whether a stool sample
that was positive by a molecular assay needs to be tested
with a confirmatory toxin assay [216] given it can also
identify toxigenic C. difficile in asymptomatic patients.
This underscores the importance of only testing patients
with symptoms. There is no evidence suggesting that
surgical patients should be diagnosed any differently
than general medical patients [217]. It has already been
highlighted that immunocompromised patients inclu-
ding those on glucocorticoids, or chemotherapy and
post-transplant patients are at increased risk for CDI.
The issue of if or when to retest for CDI is inherently
linked to the accuracy of the employed routine testing
method. Methods with suboptimal sensitivity for
C. difficile (e.g., stand-alone toxin EIAs) led to frequent
retesting in some settings. In the absence of clear changes
to the clinical presentation of suspected CDI (i.e., change
in character of diarrhea or new supporting clinical
evidence), repeating testing should not be performed.
11. CT imaging is suggested for patients with clinical
manifestations of severe-complicated C. difficile
colitis; however, its sensitivity is not satisfactory for
screening purposes (Recommendation 2 B).
In certain clinical settings, adjunct testing methods such
as radiologic diagnostic imaging may be useful for diagnos-
ing CDI. Diagnostic computed tomography (CT) imaging
can assist with an early diagnosis and may help determine
the severity of the disease in patients with CDI [218].
CT has been studied as an imaging modality for diagnos-
ing C. difficile colitis [219–222]. Typical CT findings of
CDC include colonic wall thickening, dilation,
peri-colonic stranding, “accordion sign” (high-attenua-
tion oral contrast in the colonic lumen alternating
with low-attenuation inflamed mucosa), “double-halo
sign, target sign” (intravenous contrast displaying
varying degrees of attenuation caused by submucosal
inflammation and hyperemia), and ascites [223]. How-
ever, the most common finding, colonic wall thickening, is
non-specific and can be found in other forms of colitis,
although it may be more pronounced with CDI.
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In the study by Kirkpatrick et al. [224], CT diagnosis
of CDC had a sensitivity of 52%, a specificity of 93%,
and positive and negative predictive valued 88%, and
67% respectively. Sensitivity would have been increased
to 70% with no change in specificity if colonic wall
thickness of greater than 4 mm had been used as a diag-
nostic criteria, in conjunction with the presence of the
following factors, colon wall nodularity, accordion sign,
peri-colonic stranding, or otherwise unexplained ascites.
12. Ultrasound may be useful in critically ill patients
suspected to have pseudomembranous colitis who
cannot be transported to the CT scan suite
(Recommendation 2 C).
Point-of-care ultrasound may be useful in diagnosing
and managing critically ill patients who cannot be
moved to the radiology department [225].
Ultrasound findings of pseudomembranous colitis in
severe cases include a thickened colonic wall with hetero-
geneous echogeneity as well as narrowing of the colonic
lumen [226]. Pseudomembranes can also be visualized as
hyperechoic lines covering the mucosa [226–229].
In the early stages of pseudomembranous colitis, the tex-
ture of the colonic wall is preserved. The hypoechoic
edematous mucosa and muscularis propria may be thick-
ened with the echogenic submucosa sandwiched between
them. The presence of submucosal gaps may indicate ex-
tension of tissue damage into deeper structures. Intraperito-
neal free fluid is seen in more than 70% of cases [224–227].
13. Flexible sigmoidoscopy may be helpful in the
diagnosis of C. difficile colitis when there is a high
level of clinical suspicion for C. difficile infection
(Recommendation 2 B).
Endoscopy should be used sparingly to confirm the
diagnosis of CDI since the diagnosis can be usually made
by laboratory tests, clinical findings, and imaging. How-
ever, colonoscopy may be hazardous in the setting of ful-
minant colitis where there may be increased risk of
perforation [169].
A study by Johal et al. [230] described the use of flex-
ible sigmoidoscopy as a tool for the diagnosis of C. diffi-
cile colitis when stool assays were negative suggesting
that sigmoidoscopy should be considered in all hospital-
ized patients with diarrhea in whom the stool tests for
C. difficile cytotoxin and enteric pathogens are negative.
Antibiotic therapy
14. Unnecessary antibiotic agent(s) should be
discontinued if CDI is suspected
(Recommendation 1 B).
15. Unnecessary PPIs should always be discontinued in
patients at high risk for CDI (Recommendation 1 C).
16. Empirical therapy for CDI should be avoided unless
there is a strong suspicion for CDI. If a patient has
a strong suspicion for severe CDI, empirical therapy
for CDI should be considered while awaiting test
results (Recommendation 1 C).
In cases of suspected severe CDI, antibiotic agent(s)
should be discontinued, if possible [231].
A meta-analysis addressing factors associated with pro-
longed symptoms and severe disease due to C. difficile
showed that continued use of antibiotics for infections
other than CDI is significantly associated with an
increased risk of CDI recurrence [232].
If continued antibiotic therapy is required for treat-
ment of the primary infection, antimicrobial therapy
with agents that are less frequently implicated with
antibiotic-associated CDI should be used; these include
parenteral aminoglycosides, sulfonamides, macrolides,
vancomycin, or tetracycline/tigecycline.
Although there is a clinical association between PPI
use and CDI [89], no RCTs studies have studied the rela-
tionship between discontinuing or avoiding PPI use and
risk of CDI. Thus, a strong recommendation to dis-
continue PPIs in patients at high risk for CDI regardless
of need for PPI will require further evidences. However,
stewardship activities to discontinue unneeded PPIs are
strongly warranted.
Antibiotic therapy is the first choice for CDI, and
specific antibiotic therapy guideline recommendations
should be based on the severity of the disease.
When antibiotic therapy is indicated for symptomatic
cases with a positive C. difficile toxin result, options
include metronidazole, oral or intraluminal vancomycin,
and oral fidaxomicin [233–239].
17. Oral metronidazole should be limited to the
treatment of an initial episode of mild-moderate
CDI (Recommendation 2A). Oral vancomycin is
recommended for treatment of patients with mild-
moderate disease who do not respond to
metronidazole (Recommendation 1 A). Repeated or
prolonged courses of metronidazole should be
avoided due to risk of cumulative and potentially
irreversible neurotoxicity (Recommendation 1 B).
Although metronidazole may be associated with more
frequent side effects, and there has been a significant
increase in treatment failures (especially in patients
infected with the emergent 027/BI/NAP1 strain), oral
metronidazole 500 mg three times per day for 10 days
has been used for treating mild-to-moderate cases of
CDI [240]. Repeated or prolonged courses of metronidazole
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should be avoided due to risk of cumulative and potentially
irreversible neurotoxicity [241].
In recent IDSA guidelines, metronidazole is suggested
only for patients with an initial episode of non-severe
CDI in settings where access to vancomycin or fidaxo-
micin is limited [242].
In 2015, a systematic review and meta-analysis com-
paring the efficacy and safety of metronidazole mono-
therapy with vancomycin monotherapy and combination
therapy in CDI patients was published [243]. No statisti-
cally significant difference in the rate of clinical cure was
found between metronidazole and vancomycin for mild
CDI (OR = 0.67, 95% CI 0.45–1.00; p = 0.05) or between
either monotherapy and combination therapy for CDI
(OR = 1.07, 95% CI 0.58–1.96; p = 0.83); however, the
rate of clinical cure was lower for metronidazole than
for vancomycin for severe CDI (OR = 0.46, 95% CI
0.26–0.80; p = 0.006). No significant difference in the
rate of CDI recurrence was found between metronida-
zole and vancomycin for mild CDI (OR = 0.99, 95%
CI 0.40–2.45; p = 0.98) or severe CDI (OR = 0.98, 95%
CI (0.63, 1.53); p = 0.94) or between either monothe-
rapy or combination therapy for CDI (OR = 0.91, 95%
CI (0.66, 1.26); p = 0.56). In addition, there was no
difference in the rate of adverse events (AEs) between
metronidazole and vancomycin (OR = 1.18, 95% CI
0.80–1.74; p = 0.41). In contrast, the rate of adverse
effects was significantly lower for either monotherapy
than for combination therapy (OR = 0.30, 95% CI
0.17–0.51; p < 0.0001).
However, recent data have suggested an overall supe-
riority of vancomycin to metronidazole for the treatment
of patients with CDI and oral vancomycin 125 mg four
times per day for 10 days is recommended as first choice
antibiotic also for moderate cases.
In 2017, in an update of a previously published
Cochrane review, moderate quality evidence suggested
that vancomycin is superior to metronidazole in all cases
of CDI [244]. The differences in effectiveness between
these antibiotics were not too large and the advantage of
metronidazole is its far lower cost even if liquid vanco-
mycin is cheaper and reduces the cost.
18. Both oral vancomycin or fidaxomicin are
recommended for treatment of all patients with
severe CDI (Recommendation 1 A).
19. In patients in whom oral antibiotics cannot reach
the colon, vancomycin may be administered as
retention enema via a large rectal tube or catheter
(Recommendation 1 B).
20. Fidaxomicin may be used to treat CDI, especially in
patients at higher risk for recurrence (e.g., elderly
patients or those receiving concomitant antibiotics)
(Recommendation 1A).
Vancomycin orally 125 mg four times daily for
10 days is considered superior to metronidazole in
severe C. difficile disease [245–247]. This may reflect
the superior pharmacokinetic properties of vancomycin
which is concentrated in the gut lumen. Doses of up to
500 mg have been used in some patients with severe or
fulminant, as defined as hypotension or shock, ileus or
megacolon, CDI [7], although there is little evidence for
this in the literature.
Unlike vancomycin delivered enterally, intravenous
vancomycin has no effect on CDI since the antibiotic is
not excreted into the colon. Vancomycin enema may be
an effective therapy for patients who cannot tolerate the
oral preparation or patients with ileus who have delayed
passage of oral antibiotics from the stomach to the
colon [248].
Trans-stoma vancomycin may also be effective in
surgical patients with Hartmann resection, ileostomy, or
colon diversion. A single-hospital, retrospective chart
review on 47 consecutive patients with C. difficile colitis
treated with intracolonic vancomycin (ICV) was pub-
lished by Kim et al. in 2013 [249]. Thirty-three of 47
patients (70%) with severe C. difficile colitis responded
to adjunct intracolonic vancomycin with complete reso-
lution without surgery. Multivariate analysis suggested
that failures to intracolonic vancomycin enemas
occurred in patients who were older and frail with albu-
min < 2.5 g/dl. Early surgery should be considered for
those patients. Early surgery should also be offered to
those patients who are failing maximal medical therapy
including ICV enemas.
Fidaxomicin orally 200 mg twice daily for 10 days may
be a valid alternative to vancomycin in patients with
CDI [250, 251]. Fidaxomicin was non-inferior to vanco-
mycin for initial cure of CDI in two prospective trials
[235, 236]. In a first double-blind, randomized,
non-inferiority trial [237], 629 adults with acute symp-
toms of C. difficile infection and a positive result on a
stool toxin test were enrolled and randomly assigned to
receive fidaxomicin (200 mg twice daily) or vancomycin
(125 mg four times daily) orally for 10 days. The rates of
clinical cure with fidaxomicin were non-inferior to those
with vancomycin in both the modified intention-to-treat
analysis (88.2% with fidaxomicin and 85.8% with vanco-
mycin) and the per-protocol analysis (92.1% and 89.8%,
respectively). Significantly fewer patients in the fidaxomi-
cin group than in the vancomycin group had a recurrence
of the infection, in both the modified intention-to-treat
analysis and the per-protocol analysis. In a second multi-
center, double-blind, randomized, non-inferiority trial
[238], 535 patients, 16 years or older with acute,
toxin-positive CDI were randomly allocated (1:1) to
receive oral fidaxomicin (200 mg every 12 h) or oral
vancomycin (125 mg every 6 h) for 10 days.
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Non-inferiority was shown for both the modified
intention-to-treat analysis (15.4% vs. 25.3%; p = 0.005) and
the per-protocol analysis (13.3% vs. 24.0%; p = 0.004).
Patients receiving concomitant antibiotics for other infec-
tions had a higher cure rate with fidaxomicin (46 [90.2%]
of 51) than with vancomycin (33 [73.3%] of 45; p = 0.031).
A randomized, controlled, open-label, superiority
study, recruited hospitalized adults aged 60 years and
older with confirmed CDI at 86 European hospitals ex-
tended-pulsed fidaxomicin demonstrated to be superior
to standard-dose vancomycin for sustained cure of CDI
[252]. Between Nov 6, 2014, and May 5, 2016, 364 pa-
tients were enrolled and randomly assigned to receive
extended pulsed fidaxomicin or vancomycin. Then, 362
patients received at least one dose of study medication
(181 in each group). Further, 124 (70%) of 177 patients
in the modified full analysis set receiving extended-
pulsed fidaxomicin achieved sustained clinical cure
30 days after end of treatment, compared with 106
(59%) of 179 patients receiving vancomycin (difference
11% [95% CI, 1.0–20.7]; p = 0.030; OR 1.62 [95% CI,
1.04–2.54]). Incidence of treatment-emergent adverse
events did not differ between extended-pulsed fidaxo-
micin (121 [67%] of 181) and vancomycin (128 [71%] of
181) treatment arms.
Fidaxomicin may be useful for treating patients who
are considered at high risk for recurrence (elderly
patients with multiple comorbidities who are receiving
concomitant antibiotics). However, it is important to
note that no data on the efficacy of fidaxomicin in severe
life-threatening disease are available.
The use of other antibiotics such as tigecycline
[253, 254], fusidic acid, teicoplanin, rifamixin [238],
and nitazoxanide [255] has been described in the literature,
but they are not currently recommended for general use.
Surgical management
Patients with fulminant colitis (FC) who progress to sys-
temic toxicity require surgical intervention.
To determine clinical predictors for the development
of fulminant colitis in patients with CDI, a 10-year retro-
spective review of FC patients who underwent colectomy
was performed and compared with randomly selected
age- and sex-matched non-fulminant CDI patients at a
single institution study by Girotra et al. in 2012 [256].
Predictive clinical and laboratory features included age
(> 70 years), prior CDI, profound leukocytosis (> 18,000/
mm3), hemodynamic instability, use of anti-peristaltic
medications, and a clinical trial of increasing abdominal
pain, distension and diarrhea.
Another important clinical feature that should be taken
into account in patients who are going to experience
fulminant colitis is the occurrence of a change in mental
status that could reflect significant toxemia [257].
21. Patients with severe CDI who progress to systemic
toxicity should undergo early surgical consultation
and should be evaluated for potential surgical
intervention (Recommendation 1 C).
Patients with severe CDI who progress to systemic
toxicity are likely to have serious comorbidities. Delaying
surgery in this group leads to increased likelihood of
adverse outcomes [258], although some reports show
that a short period of medical optimization can improve
outcomes before colectomy [259].
There are no reliable clinical and/or laboratory find-
ings that can predict those patients who will respond to
medical therapy and those who will need surgery [260].
Data comparing mortality rates between surgical and
medical treatment for fulminant C. difficile colitis were
published in a systematic review by Stewart et al. [261].
Five hundred ten patients with fulminant colitis were
identified in 6 studies. Emergency colectomy for patients
with FC provided a survival advantage compared with
continuing antibiotics. When all 6 studies numbering
510 patients were analyzed, the pooled adjusted odds
ratio of mortality comparing surgery with medical
therapy, and weighted by the contribution of each study,
was 0.70 (0.49–0.99) leading the authors to conclude
that emergency colectomy has a therapeutic role in
treating complicated CDI.
Patients presenting with organ failure (acute renal
failure, mental status changes, or cardiopulmonary com-
promise) also need prompt intervention since the timing
of surgical intervention is the key for survival of patients
with FC [262–265].
Seder et al. [266] described 6841 patients with CDI
and showed a decreased mortality associated with sur-
gery performed before the need for vasopressor require-
ment, especially in the patients < 65 years old. Hall et al.
[264] reviewed 3237 consecutive cases of CDI and
showed an increased mortality rate when surgical
exploration was performed after intubation or the deve-
lopment of respiratory failure and the use of vasopressors.
Recently, a risk scoring system (RSS) for daily clinical
practice was designed by van der Wilden et al. [267].
Age greater than 70 years was assigned 2 points, white
blood cell counts equal to or greater than > 20,000/μL or
equal to or less than 2000/μL was assigned 1 point, car-
diorespiratory failure was assigned 7 points, and diffuse
abdominal tenderness on physical examination was
assigned 6 points. A value of 6 points was determined to
be the threshold for reliably dividing low-risk (< 6) from
high-risk (≥ 6) patients. Only patients with cardio-
respiratory failure or diffuse abdominal tenderness were
high risk.
Ferrada et al. [268] reviewed the existing literature on
the treatment of CDI and published practice management
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guidelines (PMG) for the Eastern Association for the
Surgery of Trauma (EAST). The authors strongly recom-
mended that adult patients with CDI undergo early
surgery before developing shock and requiring vasopres-
sors. Although optimal timing remains controversial, the
authors found that it was between 3 and 5 days after diag-
nosis in patients who are worsening or not clinically
improving [268].
Many factors have been described as predictors of
mortality in patients who undergo emergency surgery.
Sailhamer et al. [269] reviewed the records of 4796
inpatients diagnosed with C. difficile colitis. In 199
patients (4.1%) with fulminant CDI, the in-hospital mor-
tality rate was 34.7%. Independent predictors of morta-
lity included age 70 years or older, severe leukocytosis or
leukopenia (white blood cell count, > or = 35,000/μL or
< 4000/μL) or bandemia (neutrophil bands, > or = 10%),
and cardiorespiratory failure (intubation or vasopres-
sors). Survival rates were higher in patients who were
cared for by surgical vs. nonsurgical departments.
The ACS-NSQIP database from 2005 to 2010 was
used by Lee et al. to study emergency open colectomies
performed for C. difficile colitis in the USA [177]. The
overall mortality was 33% (111/335). Age 80 years or
older, preoperative dialysis dependence, chronic ob-
structive pulmonary disease, and wound class III were
associated high patient mortality. Thrombocytopenia
(platelet count < 150 × 103/mm3), coagulopathy (inter-
national normalized ratio > 2.0), and renal insufficiency
(blood urea nitrogen > 40 mg/dL) were also associated
with a higher mortality.
A systematic review and meta-analysis of outcomes
following emergency surgery for CDI was published by
Banghu et al. [270]. Thirty-one studies were included,
which presented data for 1433 patients. The authors
concluded that the strongest predictors for postoperative
death were those relating to preoperative physiological
status: preoperative intubation, acute renal failure, mul-
tiple organ failure and shock requiring vasopressors.
22. Early diagnosis and treatment is important to
reduce the mortality associated with fulminant
colitis.
23. Resection of the entire colon should be
considered to treat patients with fulminant colitis
(Recommendation 1 B). However, diverting loop
ileostomy with colonic lavage is a useful
alternative to resection of the entire colon
(Recommendation 1 B).
24. Patients with fulminant colitis should be treated
with high dose vancomycin (500 mg, 6 hourly), oral
and/or by enema, in combination with intravenous
metronidazole (500 mg, 8 hourly)
(Recommendation 1 C).
In the Bhangu et al. meta-analysis [270], the most
commonly performed operation for treatment of fulmi-
nant colitis (FC) was total colectomy with end ileostomy
(89%, 1247/1401). When total colectomy with end ileos-
tomy was not performed, reoperation to resect further
bowel was needed in 15.9% (20/126). In the recent
meta-analysis by Ferrada et al. [268], 17 studies com-
paring colectomy versus other procedures or no surgery
as treatment for CDI were analyzed. The authors recom-
mended that total colectomy (versus partial colectomy
or other surgery) is the procedure of choice for patients
with C. difficile colitis.
To evaluate the role of emergency colectomy in pa-
tients with FC, and to identify subgroups of patients that
may benefit from it, Lamontagne et al. [271] published a
retrospective observational cohort study of 165 cases of
FC requiring ICU admission or prolongation of ICU stay
in 2 tertiary care hospitals in Quebec, Canada.
Eighty-seven (53%) patients died within 30 days of ICU
admission, of whom almost half (38 of 87, 44%) died
within 48 h of ICU admission. The independent predic-
tors of 30-day mortality were leukocytosis ≥ 50 × 109/L,
lactate ≥ 5 mmol/L, age ≥ 75 years, immunosuppression,
and shock requiring vasopressors. Patients who under-
went an emergency colectomy were less likely to die
than those treated medically. Colectomy was more
beneficial in patients aged 65 years or more, in
immunocompetent patients and in patients with a
leukocytosis ≥ 20 × 109/L or lactate between 2.2 and
4.9 mmol/L.
Diverting loop ileostomy with antegrade colonic lavage
may be a colon-preserving alternative to total colectomy
[272, 273]. A prospective, nonrandomized, historical
control group study was performed at the University of
Pittsburgh Medical Center and the Veterans’ Adminis-
tration Healthcare System, in Pittsburgh between June
2009 and January 2011 [272]. Forty-two patients with FC
were managed by a loop ileostomy, intraoperative co-
lonic lavage with warmed polyethylene glycol 3350/elec-
trolyte solution via the ileostomy, and postoperative
antegrade instillation of vancomycin flushes via the
ileostomy. There was no significant difference in age,
sex, pharmacologic immunosuppression, and Acute
Physiology and Chronic Health Evaluation-II scores
between the studied cohort and historical controls. The
operation was accomplished laparoscopically in 35
patients (83%). This treatment strategy resulted in
reduced mortality compared to their historical controls.
Preservation of the colon was achieved in 39 of 42 patients
(93%). Of note, vancomycin antegrade enemas were con-
tinued via the ileostomy every 6 h for 10 days and this
likely augmented the effect of the defunctioning surgery.
A retrospective multicenter study conducted under the
sponsorship of the Eastern Association for the Surgery
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of Trauma to compare loop ileostomy versus total colec-
tomy as surgical treatment for CDI was published in
2017 [274]. Data from ten centers of patients who pre-
sented with CDI requiring surgery between July 1, 2010
and July 30, 2014 were collected. When comparing
colectomy and loop ileostomy, there was no statistical
difference between these two operative strategies.
Univariate pre-procedure predictors of mortality were
age, lactate, timing of operation, vasopressor use, and
acute renal failure. There was no statistical difference
between the APACHE score of patients undergoing
either procedure (TC, 22 vs. LI, 16). Adjusted mortality
(controlled for pre-procedure confounders) was signifi-
cantly lower in the loop ileostomy group (17.2% vs. 39.7%;
p = 0.002).
Supportive care
25. Early detection of shock and aggressive
management of underlying organ dysfunction are
essential for improved outcomes in patients with
fulminant colitis (Recommendation 1 C).
Supportive measures, including intravenous fluid
resuscitation, albumin supplementation, and
electrolyte replacement, should be provided to all
patients with severe C. difficile infection
(Recommendation 1 C).
Early detection and prompt aggressive treatment of
the underlying organ dysfunction is an essential compo-
nent in the management of CDI in critically ill patients.
Severe CDI may present with a fulminant course and
may be associated with great morbidity and high morta-
lity. Physiologic support including invasive monitoring
in an intensive care unit and aggressive resuscitation are
often necessary in fulminant colitis. Diarrhea results in
significant volume depletion and electrolyte abnor-
malities, and fluid and electrolyte imbalance should be
promptly corrected.
Although it has been debated, albumin supplementa-
tion in patients with severe hypoalbuminemia (< 2 g/dl)
should be considered as a supportive measure and also
to exploit its anti-toxin properties [275].
The expert panel suggests measuring intra-abdominal
pressure (IAP) when any known risk factor for intra-ab-
dominal hypertension (IAH)/abdominal compartment
syndrome (ACS) is present.
RCDI
Recurrence is diagnosed when CDI recurs < 8 weeks after
the resolution of a previous episode, provided the symp-
toms from the previous episode resolved after completion
of the initial treatment and other causes have been
excluded. Symptomatic recurrent C. difficile infection
(RCDI) occurs in approximately 20% of patients and is
challenging [141]. Therefore, patients with recurrent CDI
should therefore be treated by experienced clinicians.
26. Agents that may be used to treat the first
recurrence of CDI include vancomycin (particularly
if metronidazole was used for the first episode) or
fidaxomicin. (Recommendation 1 B).
27. Antibiotic treatment options for patients with > 1
recurrence of CDI include oral vancomycin therapy
using a tapered and pulsed regimen
(Recommendation 1C).
For recurrent cases of CDI, oral vancomycin 125 mg
four times per day for 14 days or oral fidaxomicin
200 mg twice a day for 10 days is recommended for first
recurrence.
Metronidazole is not recommended as initial treat-
ment of recurrent CDI as sustained response rates are
lower than those with vancomycin. Furthermore, metro-
nidazole should not be used for long-term therapy
because of the potential for cumulative neurotoxicity.
Vancomycin and fidaxomicin are equally effective in
resolving CDI symptoms but fidaxomicin has been
shown to be associated with a lower likelihood of CDI
recurrence after a first recurrence [237, 238, 276]. How-
ever, there are no prospective randomized controlled
trials investigating the efficacy of fidaxomicin in patients
with multiple recurrences of CDI. Vancomycin is often
administered using a prolonged tapered and/or pulsed
regimen which may be more effective than a standard 10
to 14 days course, although no RCTs have been reported
in second or subsequent CDI recurrences [146].
Probiotics
28. Limited direct evidence exists to support the use of
probiotics in the management of a first episode of
CDI as an adjunctive treatment to antibiotics for
immunocompetent patients Recommendation 2 B).
The altered composition of gut microbiota in the set-
ting of C. difficile infection has raised interest in the po-
tential role of probiotics [163]. Their use aims to
re-colonize and restore the diversity of flora following
the disruption due to antibiotic treatment and C. difficile
overgrowth.
There is limited direct evidence to support the use of
probiotics in the primary prevention of CDI.
Data for primary prevention of CDI often arises from
prevention of antibiotic-associated diarrhea trials with
CDI as a secondary outcome and are often under-
powered for CDI. Thus, meta-analyses may be useful to
evaluate if specific probiotics are efficacious for CDI, as
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this statistical method utilizes the increase in power
resulting from pooling different studies together. How-
ever, since the recent finding that the efficacy of probio-
tics are both strain-specific and disease-specific [277],
for valid conclusions to be reached, the meta-analysis
must assess efficacy within subgroups of identical pro-
biotic strains (or mixture of strains) and for the same
type of disease. A meta-analysis of 22 randomized con-
trolled trials using sub-group analysis for 5 different
types of probiotics for primary prevention of CDI found
4/5 (Saccharomyces boulardii I-745, Lactobacillus casei
DN114001, a mixture of Lactobacillus acidophilus and
Bifidobacterium bifidum, and another mixture of three
Lactobacilli strains [L. acidophilus CL1285, L. casei
LBC80R, Lactobacillus rhamnosus CLR2]) were effective
and one type (L. rhamnosus GG) was not effective [278].
Other systematic reviews and meta-analyses report a
protective effect of probiotics [279–284], but reviews ex-
ploring the contribution of probiotics in CDI prevention
can be limited due to heterogeneity between studies,
inadequate study power, or significant levels of missing
outcome data. In addition, many reviews still fail to
account for strain-specificity and pool different types of
probiotics together in their analysis [280, 281, 284]. The
short-term use of probiotics appeared to be safe and
effective when used along with antibiotics in patients
who are not immunocompromised or severely debili-
tated. Probiotics should not be administered to patients
at risk of bacteremia or fungemia.
29. Prophylactic probiotics may be considered for
inpatients receiving antibiotics during high-risk
period (such as outbreaks) before the disease de-
velops (Recommendation 2 C). Probiotics should be
not used in immunocompromised patients (Recom-
mendation 2 C).
Several types of probiotics have been tested on a
facility-level intervention as part of an infection control
bundle for CDI. In an effort to reduce hospital-wide CDI
rates (especially in hospitals having CDI outbreaks), pro-
biotics were given to newly admitted patients receiving
antibiotics and continued during either the duration of
the antibiotic or duration of the patient’s stay. Although
lacking in the rigorous strength from randomized trials,
these hospital studies showed a significant reduction of
CDI rates for some types of probiotics (L. casei Shirota,
Lactobacillus plantarum 299v, and a mixture of three
lactobacilli strains, Bio-K+) [278]. This three lactobacilli
strain mixture (L. acidophilus CL1285, L. casei LBC80R,
and L. rhamnosus CLR2) has been tested in seven other
hospitals and found to be effective in reducing CDI rates
[285]. However, other types of probiotics need further
research, particularly in those at high risk of CDI.
Probiotics are contraindicated for immunocompromised
patients due to a rare, but serious risk of bacteremia.
30. Probiotics for prevention of recurrent CDI may be
an effective adjunct to standard antibiotic treatment
(vancomycin) in patients with at least one prior
episode of CDI (Recommendation 2 B).
There have been many case reports and case series
reporting fewer recurrences of CDI when some probio-
tics were used as an adjunctive treatment with vanco-
mycin or metronidazole. However, there are fewer
randomized trials for this adjunctive therapy. Two ran-
domized controlled trials found significantly fewer CDI
patients developed recurrences when Saccharomyces
boulardii I-745 was combined with standard antibiotic
therapy [286, 287]. The first trial demonstrated a lower
CDI recurrence rate compared with a placebo control
group (26% vs. 45%, respectively) [283] and the second
trial found that the combination of S. boulardii (1 g/day)
with high dose vancomycin (2 g/day) was more effective
than high dose vancomycin and placebo (17% vs. 50%
recurrence rate) [284]. The probiotic was not able to
reduce CDI recurrences when combined with a lower
dose of vancomycin (500 mg/day) or with metronidazole
(1 g/day). Other studies with Lactobacillus strains
(L. rhamnosus GG or L. plantarum 299v) were stopped
prematurely due to enrollment problems [146]. There
have no published trials currently combining probiotics
with fidaxomicin.
Fecal microbiota transplantation
31. Fecal microbiota transplantation (FMT) may be an
effective option for patients with multiple
recurrences of CDI who have failed appropriate
antibiotic treatments (Recommendation 2 C).
FMT has been considered as an alternative therapy to
treat RCDI [283–293]. It involves infusing intestinal
microorganisms (in a suspension of healthy donor stool)
into the intestine of patients to restore the intestinal
microbiota.
The rationale of FMT is that disruption of the normal
balance of colonic flora allows C. difficile strains to grow
and produce CDI. By reintroducing normal flora via
donor feces, the imbalance may be corrected, and nor-
mal bowel function re-established [288].
FMT has not been widely adopted as a therapeutic
tool probably due to concerns regarding safety and
acceptability [258].
A systematic literature review of FMT treatment for
RCDI and pseudomembranous colitis was published in
2011 by Gough et al. [289]. In 317 patients treated
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across 27 case series and reports, FMT was highly effec-
tive, showing disease resolution in 92% of cases. In those
studies, 35% of patients received FMT via enema, with a
response rate of 95%; 23% patients received FMT via
naso-jejunal tube by gastroscope, with a response rate of
76%; and 19% via colonoscopy, with a response rate of
89%. Effectiveness varied by route of instillation,
relationship to stool donor, volume of FMT given, and
treatment before infusion.
Another systematic review was published by
Cammarota et al. [290]. Twenty full-text case series, 15
case reports, and 1 randomized controlled study were
included for the final analysis. Almost all patients treated
with donors’ fecal infusion had experienced recurrent
episodes of CD-associated diarrhea despite standard
antibiotic treatment. Of a total of 536 patients treated,
467 (87%) had resolution of diarrhea. Diarrhea reso-
lution rates varied according to the site of infusion:
81% in the stomach, 86% in the duodenum/jejunum,
93% in the cecum/ascending colon, and 84% in the
distal colon. No severe adverse events were reported
with the procedure.
Recently, a review to evaluate the efficacy of FMT in
treating recurrent and refractory CDI was published
[291]. Thirty-seven studies were included; 7 randomized
controlled trials and 30 case series. FMT was more
effective than vancomycin (RR = 0.23, 95% CI 0.07–0.80)
in resolving recurrent and refractory CDI. Clinical reso-
lution across all studies was 92% (95% CI 89–94%). A
significant difference was observed between lower
gastrointestinal (GI) and upper GI delivery of FMT 95%
(95% CI 92–97%) vs. 88% (95% CI 82–94%) respectively
(p = 0.02). There was no difference between fresh and fro-
zen FMT 92% (95% CI 89–95%) vs. 93% (95% CI 87–97%)
respectively (p = 0.84). Administering consecutive courses
of FMT following failure of first FMT resulted in an incre-
mental effect. Donor screening was consistent but
variability existed in recipient preparation and volume of
FMT. Serious adverse events were uncommon.
Although FMT has high success rates with long-term
durability [292], few disadvantages still exist. In particu-
lar, the manipulation of feces and the classical enteral
administration methods are not only laborious but tend
to make the procedure rather unattractive for physicians
and patients.
In the context of these disadvantages, few efforts have
been made to enhance the feasibility and social acceptance
of microbiota transplantation.
FMT may be administered via enemas or as a slurry
given via a nasogastric tube.
One systematic review which compared various routes of
administration included a total of 182 patients (148 received
FMT via colonoscopy and 34 received FMT via nasogastric
tube) from 12 published studies [293]. Recurrence of CDI
after FMT was similar in both the colonoscopy group
(8/148, 5.4%) versus the nasogastric tube group (2/34,
5.9%) (p = 1.000). However, the overall rate of cure
after FMT was slightly higher in patients receiving
FMT by colonoscopy: 85.3% (29 patients, 29/34) in
the nasogastric tube group and 93.2% (138 patients,
138/148) in the colonoscopy group (p = 0.162).
A larger and more recent systematic review of 14 stud-
ies including 305 patients and comparing FMT delivery by
upper and lower gastrointestinal routes also favored lower
gastrointestinal delivery [294]. At 30 and 90 days, the risk
of clinical failure was 5.6% and 17.9% in the upper gastro-
intestinal group compared with 4.9% and 8.5% in the
lower GI delivery route group, respectively.
More recently, encapsulated preparations of FMT have
been used with success. This strategy has the advantage
of being less invasive and simpler, which may also result
in improved cost-effectiveness [295–298].
In 2014, Youngster et al. [296] reported their expe-
rience with frozen FMT capsules in 20 patients who had
RCDI. Fourteen patients (70%) had resolution of diar-
rhea after a single treatment, and 4 patients responded
after a second treatment, with a clinical resolution rate
of 90%.
Patients who are immunocompromised are at increased
risk of CDI. During the last 2 years, the first data on FMT
in immunocompromised patients began to appear in the
medical literature [299].
A multicenter retrospective series on the use of FMT
in immunocompromised patients with recurrent, refrac-
tory, or severe CDI was published in 2014 [300].
Immunosuppression included HIV/AIDS (3), solid organ
transplantation (19), oncologic condition (7), immuno-
suppressive therapy for IBD (36), and other medical con-
ditions/medications (15). This series demonstrated the
effective use of FMT for CDI in immunocompromised
patients with few serious adverse events.
With the increased awareness of the role of native gut
microbiome and its role in the gut brain axis, there have
been concerns about the long-term effect of transplanted
stool, and how the new gut microbiome can affect brain
function and immune responses.
Monoclonal antibodies
32. Coadjuvant treatment with monoclonal antibodies
(bezlotoxumab) may prevent recurrences of CDI,
particularly in patients with CDI due to the 027
epidemic strain, in immunocompromised patients
and in patients with severe CDI
(Recommendation 1 A).
Since the expression of clostridial toxins (TcdA and
TcdB) is mandatory for the development of CDI, the
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development of monoclonal antibodies aimed at pre-
venting the cytotoxic effect of these toxins is a potential
strategy for controlling the disease. In 2016, the FDA
approved bezlotoxumab to reduce the recurrence of CDI
in adult patients receiving antimicrobial therapy for CDI
who are at high risk of CDI recurrence. Bezlotoxumab
(MK-6072) is a human monoclonal antibody which
reduces recurrent CDI by blocking the binding of C. difficile
toxin B to host cells, thus limiting epithelial damage
and facilitating recovery of the microbiome [301].
Besides bezlotoxumab, another human monoclonal
antibody, actoxumab (MK-3415), was recently designed
to neutralize C. difficile toxin.
The data from two double-blind, randomized, placebo-
controlled, phase 3 trials, MODIFY I and MODIFY II,
involving 2655 adults receiving oral standard-of-care
antibiotics for primary or recurrent C. difficile infection
showed that bezlotoxumab achieved a significant bene-
fit over placebo in the treatment of recurrent CDI. Par-
ticipants received an infusion of bezlotoxumab (10 mg/kg
of body weight), actoxumab plus bezlotoxumab (10 mg/kg
each), or placebo; actoxumab alone (10 mg/kg) was
given in MODIFY I but discontinued after a planned
interim analysis. The primary end point was recurrent
infection (new episode after initial clinical cure) within
12 weeks after infusion in the modified intention-
to-treat population [302].
In both trials, the rate of recurrent C. difficile infection
was significantly lower with bezlotoxumab alone than with
placebo (MODIFY I: 17% [67 of 386] vs. 28% [109 of 395];
adjusted difference, − 10.1 percentage points; 95% CI, − 15.9
to − 4.3; p < 0.001; MODIFY II: 16% [62 of 395] vs. 26%
[97 of 378]; adjusted difference, − 9.9 percentage
points; 95% CI, − 15.5 to − 4.3; p < 0.001) [303].
A post-hoc analysis of pooled monoclonal antibodies for
C. difficile therapy (MODIFY) I/II data assessed bezlotox-
umab efficacy in participants with risk factors for RCDI
including age ≥ 65 years, history of CDI, compromised
immunity, severe CDI, and ribotype 027/078/244 [304].
Although the patients with only one of the risk factors
may benefit from bezlotoxumab, patients with at least
three risk factors appeared to have the greatest risk
reduction with bezlotoxumab.
Intravenous immunoglobulin
33. Intravenous immunoglobulin (IVIG) should only be
used as adjunct therapy in patients with multiple
recurrent or fulminant CDI until results from large,
randomized controlled trials are available
(Recommendation 2 C).
Novel treatment modalities for management of CDI
have been developed. IVIG treatment is based on
evidence that the level of immune response to C. difficile
colonization is the major determinant of the magnitude and
duration of clinical manifestations. Passive immunization
with IVIG has been successful in several small series. A
review by Abourgergi et al. [305] of 15 small, mostly
retrospective and non-randomized studies, documented
success with IVIG in the treatment of protracted, recur-
rent, or severe CDI. The authors concluded that IVIG
should only be used as adjunct therapy until results
from large, randomized controlled trials are available.
Two small retrospective matched cohort studies were pub-
lished that compared the clinical efficacy of the addition of
IVIG to conventional CDI treatment [306, 307]. Neither of
these studies found significant differences between the
compared cohorts in the main clinical outcomes, although
Shahani et al. [306] noted that in their IVIG cohort, there
were significantly older patients with more severe CDI
than in the control group. It is reasonable to utilize IVIG
therapy in patients diagnosed with hypogammaglobumine-
mia based on the confirmation of IgG levels below the
normal laboratory range.
Enteral nutrition in CDI
34. Tube feeding patients should be clinically assessed
due to their risk for developing CDI
(Recommendation 2 C).
It is widely accepted that enteral nutrition (EN) main-
tains gut mucosal integrity which leads to decreased in-
testinal permeability, decreased infections, and an
improved immunological status. EN during episodes of
diarrhea may be well tolerated and may improve enterocyte
healing and maintenance of enzyme activity [308–310].
Enteral nutrition, however, has also been associated with
increased risk of CDI [310]. Bliss et al. evaluated 76
tube-fed and non-tube-fed hospital patients for the deve-
lopment of CDI [311]. Patients were controlled for age,
severity of illness, and duration of hospitalization. Patients
who were tube-fed were statistically more likely to develop
CDI (20% vs. 8% p = 0.03). One of the reasons may be pro-
longed use of elemental diets. It is known that critically ill
patients tolerate feeding well if the feed is given in elemen-
tal form and delivered beyond the stomach into the
jejunum because it is totally absorbed within the upper
small intestine [312], depriving the colonic microbiota of
their source of nutrition, such as dietary fibers, fructose
oligosaccharides, and resistant starch [313]. The resultant
suppression of colonic fermentation may therefore lead to
the disruption of the normal gut flora and the creation of a
“permissive” environment for C. difficile colonization and
subsequent infection. In feeding tube patients, the conver-
sion of elemental diet feeding to a diet containing adequate
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indigestible carbohydrate after the first week of critical ill-
ness may, in theory, be beneficial.
Puri et al. [314] reported that daily concomitant treat-
ment with 4 g cholestyramine in patients receiving long-
term intravenous ceftriaxone (2 to 4 g ceftriaxone
daily, for an average of > 10 weeks) was associated
with CDI in only 3 out of 46 patients (6.5%) com-
pared with 23.1% of those receiving ceftriaxone alone.
Cholestyramine (or colestyramine) is a hydrophilic,
water insoluble, non-digestible basic anion-exchange
resin which can bind luminal TcdA and TcdB.
Anti-motility agents
35. The use of anti-peristaltic agents for the treatment
of CDI should be discouraged. If anti-peristaltic
agents are used to control persistent symptoms in
patients with CDI, they must always be accom-
panied by medical therapy (Recommendation 2 C).
A review of the literature regarding anti-motility treat-
ment of CDI found 55 patients with CDI who were
exposed to anti-motility agents [315]. Nine patients
(16%) died, and 27 patients (49%) had unknown out-
comes. Seventeen patients (31%) with CDI developed
colonic dilation; 5 of these patients with severe CDI
died. However, all patients who experienced complications
or died were given anti-motility agents alone initially,
without an appropriate antibiotic and 23 patients who
received metronidazole or vancomycin co-administered
with the anti-motility agent experienced no complications.
Further study of the role of anti-motility agents in pro-
viding symptomatic relief and reducing environmental
contamination with infectious stool may be warranted
though, until there is clear evidence of benefit, their use in
patients with CDI should be avoided.
Conclusions
In the last three decades, the worldwide increase in CDI
incidence has been particularly apparent among surgical
patients, becoming a global public health challenge.
Therefore, prompt and precise diagnosis is paramount
for the effective management of CDI, allowing both the
immediate implementation of infection prevention and
control strategies, and the optimization of treatment in
surgical patients, considering the most recent changes
introduced in the management of this infection.
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